DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

by · The Cerbat Gem

DexCom, Inc. (NASDAQ:DXCM – Get Free Report) has received an average rating of “Moderate Buy” from the eighteen brokerages that are presently covering the stock, Marketbeat reports. Six analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $104.59.

Several analysts have recently weighed in on the stock. Morgan Stanley lowered their price objective on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research report on Friday, July 26th. Barclays cut their target price on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research note on Monday, July 29th. Baird R W lowered shares of DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. JPMorgan Chase & Co. lifted their target price on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Finally, Leerink Partners cut their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th.

Get Our Latest Analysis on DexCom

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $70.48 on Friday. The company has a 50 day moving average of $69.92 and a 200 day moving average of $96.37. The stock has a market cap of $27.53 billion, a P/E ratio of 42.20, a P/E/G ratio of 2.26 and a beta of 1.18. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On DexCom

Hedge funds and other institutional investors have recently made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of DexCom in the second quarter valued at $25,000. Sachetta LLC raised its stake in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 171 shares during the period. Crewe Advisors LLC purchased a new stake in shares of DexCom in the first quarter valued at $29,000. Riverview Trust Co raised its stake in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares during the period. Finally, DT Investment Partners LLC raised its stake in shares of DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 315 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

(Get Free Report

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Further Reading